UNSPSC 51162742: Telmesteine

This classification denotes a mucolytic agent with the molecular formula C7H11NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 124I3FE35T, chemically known as (-)-3-ethyl hydrogen (r)-3,4-thiazolidinedicarboxylate but more generally known as telmesteine, which bears US NIH Compound Identifier 65946. European Medicines Agency schedules Telmesteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10873MIG.

UNSPSC 51162742 Telmesteine, a Commodity code, encompasses pharmaceutical products procured by state and local governments for emergency response, public health, and clinical applications. Recent solicitations show state and local buyers acquiring naloxone (opioid antagonist medications) and safe drug deactivation systems for community health programs, as well as generic multi-source pharmaceuticals and over-the-counter products distributed through state and local medical facilities and cooperative purchasing networks. The issuing bodies include county health departments, state procurement offices, and multistate cooperative purchasing alliances serving state and local member agencies. Work under this code involves product sourcing, pricing negotiation, regulatory compliance certification (cGMP, DSCSA, FDA requirements), supply-chain management through authorized pharmaceutical wholesalers, and delivery logistics to public health facilities.

Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2026) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with bidders required to include shipping costs and provide unit pricing for each line item. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP posted January 20, 2026 (questions due February 18, 2026; proposals due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local facilities across Minnesota and Oregon; awarded vendors must supply through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, or Morris & Dickson Co., LLC, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on compliance and EDI capability. Both solicitations require E-Verify compliance, drug-free workplace certification, and comprehensive insurance including commercial general liability coverage.